ME01803B - Humanizovani anti-cmet antagonisti - Google Patents
Humanizovani anti-cmet antagonistiInfo
- Publication number
- ME01803B ME01803B MEP-2010-306A MEP30610A ME01803B ME 01803 B ME01803 B ME 01803B ME P30610 A MEP30610 A ME P30610A ME 01803 B ME01803 B ME 01803B
- Authority
- ME
- Montenegro
- Prior art keywords
- antibody
- seq
- sequence
- cancer
- follows
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (47)
1. Humanizovana forma anti-c-met antitela glodara sadrži: (a) najmanje jednu HVR sekvencu odabranu iz grupe koju čine: (i) HVR-L1 sadrži sekvencu A1-A17, gde A1-A17 predstavlja KSSQSLLYTSSQKNYLA, (ii) HVR-L2 sadrži sekvencu B1-B7, gde B1-B7 predstavlja VVASTRES, (iii) HVR-L3 sadrži sekvencu C1-C9, gde C1-C9 predstavlja QQYYAYPWT, (iv) HVR-40H1 sadrži sekvencu Dl-DIO, gde D1-D10 predstavlja GYTFTSYWLH, and (v) HVR-H2 sadrži sekvencu E1-E18, gde E1-E18 predstavlja GMIDPSNSOTRFNPNFKD; i (b) varianta HVR-H3 sadrži sekvencu TYRSYVTPLDY, SYRSYVTPLDY, TYSSYVTPLDY, SYSSY-VTPLDY, TYSSYVTSLDY ili TYSSYVTALDY gde je monovalentni afinitet pomenutog antitela za humani c-met veći nego monovalentni afinitet antitela glodara koje sadrži varijabilnu sekvencu lakog lanca prikazanu kao SEQ ID NO: 9 i varijabilnu sekvencu teškog lanca prikazanu kao SEQ ID NO: 10 i ovde pomenuto antitelo inhibira c-met-zavisnu ćelijsku proliferaciju bolje od referentnog antitela koje sadrži himerično anti-c-met antitelo koje sadrži varijabilnu sekvencu lakog lanca i teškog lanca prikazanu kao SEQ ID NO: 509 i 10 kako sledi,
2. Antitelo iz patentnog zahteva 1, gde je najmanje deo okvir sekvence humana konsenzus okvir sekvenca. , sadrži varijantu HVR-55L
3. Antitelo iz patentnog zahteva 1, koja sadrži sekvencu prikazanu kao SEQ ID NO: 72.
4. Antitelo iz patentnog zahteva 1, sadrži varijantu HVR-H2 koja sadrži sekvencu prikazanu kao SEQ ID NO: 98.
5. Antitelo iz patentnog zahteva 1 sadrži HVR-L1 koji ima sekvencu od SEQ ID NO: l.
6. Antitelo iz patentnog zahteva 1 sadrži HVR-L3 koji ima sekvencu od SEQ ID NO: 3.
7. Antitelo iz patentnog zahteva 1, gde varijanta HVR-H3 sadrži sekvencu TYRSYVTPLDY, TYSSYVTPLDY, TYSSYVTSLDY ili TYSSYVTALDY.
8. Antitelo iz patentnog zahteva 1, gde je monovalentni afinitet antitela za humani c-met najmanje 3-ostruko veći od monovalentnog afiniteta antitela glodara sadrži varijabilnu sekvencu lakog lanca i teškog lanca prikazanog kao SEQ ID NO: 9 i 10 na SI. 7.
9. Humanizovano antitelo iz patentnog zahteva 1, gde je antitelo glodara produkovano pomoću hibridoma ćelijske linije čuvane kao American Type Culture Collection Accession Number ATCC sa oznakom HB-11895 (hybridoma 5D5. 11. 6).
10. Antitelo iz patentnog zahteva 1, gde je afinitet za vezivanje izražen kao Kd vrednost.
11. Antitelo iz bilo kog od patentnih zahteva 1, 8 ili 9, gde je afinitet za vezivanje meren pomoću Biacore ili radioimunoeseja.
12. Antitelo iz patentnog zahteva 1 sadrži humanu k subgrupu 1 konsenzus okvir sekvence.
13. Antitelo iz patentnog zahteva 1 sadrži teški lanac humane subgrupe III konsenzus okvir sekvence.
14. Antitelo iz patentnog zahteva 13 gde okvir sekvenca sadrži supstituciju na poziciji 71, 73 i/ili 78.
15. Antitelo iz patentnog zahteva 14 gde je pomenuta supstitucija R71 A, N73T i/ili N78A.
16. Antitelo iz patentnog zahteva 1, gde humanizovano antitelo inhibira vezivanje humanog faktora rasta hepatocita za njegov receptor bolje nego referentno antitelo koje podrazumeva himerično anti-c-met antitelo koje sadrži variabilnu sekvencu lakog lanca i teškog lanca prikazanu kao SEQ ID NO: 9 i 10 kako sledi.
17. Antitelo iz patentnog zahteva 16, gde antitelo inhibira vezivanje sa vrednosti IC50 koja je manja od polovine one koju ima himerično antitelo.
18. Antitelo iz patentnog zahteva 17, gde je IC50 određen preko opsega koncentracija antitela od oko 0. 01 nM do oko 1000 nM.
19. Antitelo iz patentnog zahteva 1, gde humanizovano antitelo inhibira aktivaciju receptora humanog faktora rasta hepatocita (HGF) bolje nego referentno antitelo koje podrazumeva himerično anti-c-met antitelo koje sadrži varijabilnu sekvencu lakog lanca i teškog lanca prikazanu kao SEQ ID NO: 9 i 10 kako sledi.
20. Antitelo iz patentnog zahteva 19, gde antitelo inhibira aktivaciju receptora sa vrednosti IC50 koja je manja od polovine one koju ima himerično antitelo.
21. Antitelo iz patentnog zahteva 20, gde je IC50 određen preko opsega koncentracija antitela od oko 0. 1 rtM do oko 100 nM.
22. Antitelo iz patentnog zahteva 1, gde humanizovano antitelo inhibira proliferaciju ćelija sa vrednosti IC50 koja je manja od polovine one koju ima himerično antitelo.
23. Antitelo iz patentnog zahteva 22, gde je IC50 određen preko opsega koncentracija antitela od oko 0. 01 nM do oko 100 nM.
24. Antitelo iz bilo kog predhodnog patentnog zahteva, gde su oba, humanizovano antitelo i himerično antitelo monovalentna.
25. Antitelo iz predhodnih patentnih zahteva, gde oba, humanizovano antitelo i himerično antitelo sadrže pojedinačni Fab region vezan za Fc region.
26. Antitelo iz patentnog zahteva 1 sadrži varijabilni domen teškog lanca koji sadrži HVR1-HC, HVR2-HC i HVR3-HC sekvence prikazane kao SEQ ID NO: 191-193 kako sledi.
27. Antitelo iz patentnog zahteva 26, gde varijabilni domen sadrži FR1-HC, FR2-HC, FR3-HC i R4-HC sekvence prikazane kao SEQ ID NO: 187-190 kako sledi.
28. Antitelo iz patentnog zahteva 26 ili 27, gde antitelo sadrži CH1 i/ili Fc prikazan kao SEQ ID NO: 194 i 195 kako sledi.
29. Antitelo iz patentnog zahteva 1 sadrži varijabilni domen lakog lanca koji sadrži HVR1-LC, HVR2-LC i HVR3-LC sekvence prikazane kao SEQ ID NO: 183-185 kako sledi.
30. Antitelo iz patentnog zahteva 29, gde varijabilni domen sadrži FR1-LC, FR2-LC, FR3-LC i FR4-LC sekvence prikazane kao SEQ ID NO: 179-182 kako sledi.
31. Antitelo iz patentnog zahteva 29 ili 30, gde antitelo sadrži CL1 sekvencu prikazanu kao SEQ ID NO: 186.
32. Antitelo sadrži varijabilni domen teškog lanca iz bilo kog od patentnih zahteva 26 do 28 i varijabilni domen lakog lanca iz bilo kog od patentnih zahteva 29 do 31.
33. Antitelo iz patentnog zahteva 32 sadrži varijabilni domen teškog lanca koji sadrži HVR1-HC, HVR2-HC i HVR3-HC sekvence prikazane kao SEQ ID NO: 191-193 kako sledi, FR1-HC, FR2-HC, FR3-HC i FR4-HC sekvence prikazane kao SEQ ID NO: 187-190 kako sledi, i CH1 i Fc prikazan kao SEQ ID NO: 194 i 195 kako sledi, i varijabilni domen lakog lanca koji sadrži HVR1-LC, HVR2-LC i HVR3-LC sekvence prikazane kao SEQ ID NO: 183-185 kako sledi, FR1-25LC, FR2-LC, FR3-LC i FR4-LC sekvence prikazane kao SEQ ID NO: 179-182 kako sledi, i CL1 sekvenca prikazana kao SEQ ID NO: 186.
34. Antitelo iz patentnog zahteva 32 ili 33, gde je antitelo monovalentno i sadrži Fc region.
35. Antitelo iz patentnog zahteva 34, gde Fc region sadrži prvi i drugi polipeptid, gde svaki prvi i drugi polipeptid sadrži jednu ili više mutacija u odnosu na nekultivisani tip humanog Fc.
36. Antitelo iz patentnog zahteva 35, gde prvi polipeptid sadrži Fc sekvencu prikazanu kao SEQ ID NO: 195 i drugi polipeptid sadrži sekvencu prikazanu kao SEQ ID NO: 196.
37. Antitelo iz bilo kog predhodnog patentnog zahteva za korišćenje u metodi tretmana.
38. Antitelo iz bilo kog predhodnog patentnog zahteva za korišćenje u metodi tretmana karcinoma.
39. Antitelo iz patentnog zahteva 38, gde karcinom predstavlja karcinom pluća, karcinom mozga, karcinom bubrega, karcinom želuca, kolorektalni karcinom i/ili karcinom pankreasa.
40. Antitelo iz bilo kog od patentnih zahteva 1 do 36 za korišćenje u metodi tretmana proliferativnih poremećaja.
41. Korišćenje antitela iz bilo kog od patentnih zahteva 1 do 36 u preparatima medikamenata za tretman karcinoma.
42. Korišćenje iz patentnog zahteva 41, gde karcinom predstavlja karcinom pluća, karcinom mozga, karcinom bubrega, karcinom želuca, kolorektalni karcinom i/ili karcinom pankreasa.
43. Korištenje antitela iz bilo kog od patentnih zahteva 1 do 36 u preparatima medikamenata za tretman proliferativnih poremećaja.
44. Nukleinska kiselina koja kodira antitelo iz bilo kog od patentnih zahteva 1-36.
45. Ćelija domaćin sadrži nuklensku kiselinu iz patentnog zahteva 44.
46. Preparat koji sadrži antitelo iz bilo kog od patentnih zahteva 1-36.
47. Preparat iz patentnog zahteva 46, gde preparat sadrži nosač.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59899104P | 2004-08-05 | 2004-08-05 | |
| EP05804027A EP1773885B1 (en) | 2004-08-05 | 2005-08-04 | Humanized anti-cmet antagonists |
| PCT/US2005/027626 WO2006015371A2 (en) | 2004-08-05 | 2005-08-04 | Humanized anti-cmet antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01803B true ME01803B (me) | 2010-12-31 |
Family
ID=35787927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2010-306A ME01803B (me) | 2004-08-05 | 2005-08-04 | Humanizovani anti-cmet antagonisti |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US7476724B2 (me) |
| EP (1) | EP1773885B1 (me) |
| JP (2) | JP5068651B2 (me) |
| KR (1) | KR101397851B1 (me) |
| CN (3) | CN101035808B (me) |
| AT (1) | ATE465181T1 (me) |
| AU (1) | AU2005267720B2 (me) |
| BR (1) | BRPI0513666A (me) |
| CA (1) | CA2575402A1 (me) |
| CY (1) | CY1111622T1 (me) |
| DE (1) | DE602005020799D1 (me) |
| DK (1) | DK1773885T3 (me) |
| ES (1) | ES2344793T3 (me) |
| HR (1) | HRP20100385T1 (me) |
| IL (3) | IL180588A (me) |
| ME (1) | ME01803B (me) |
| MX (1) | MX2007001470A (me) |
| NO (1) | NO20071188L (me) |
| NZ (1) | NZ552485A (me) |
| PL (1) | PL1773885T3 (me) |
| PT (1) | PT1773885E (me) |
| RS (1) | RS51326B (me) |
| RU (1) | RU2398777C2 (me) |
| SI (1) | SI1773885T1 (me) |
| WO (1) | WO2006015371A2 (me) |
| ZA (1) | ZA200701656B (me) |
Families Citing this family (221)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CA2575402A1 (en) * | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US8288352B2 (en) * | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| JP5171611B2 (ja) * | 2005-03-25 | 2013-03-27 | ナショナル リサーチ カウンシル オブ カナダ | 可溶性ポリペプチドの単離方法 |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2008030122A1 (en) | 2006-09-07 | 2008-03-13 | University Of Otago | Biomarkers |
| JP2010502224A (ja) * | 2006-09-08 | 2010-01-28 | アボット・ラボラトリーズ | インターロイキン１３結合タンパク質 |
| US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
| EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| AU2016228280B2 (en) * | 2007-07-12 | 2019-02-21 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| AU2014200629B2 (en) * | 2007-07-12 | 2016-10-06 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| EP2176295B1 (en) | 2007-07-16 | 2014-11-19 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| PE20090943A1 (es) | 2007-07-16 | 2009-08-05 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
| US20090035848A1 (en) * | 2007-08-03 | 2009-02-05 | Robert Hickey | Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products |
| US20090148905A1 (en) | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
| KR101607346B1 (ko) | 2008-01-31 | 2016-03-29 | 제넨테크, 인크. | 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법 |
| KR20100135780A (ko) * | 2008-03-06 | 2010-12-27 | 제넨테크, 인크. | Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법 |
| CA2716670A1 (en) * | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| EP2271941B1 (en) * | 2008-03-07 | 2012-08-08 | OSI Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| AU2009224113B2 (en) * | 2008-03-12 | 2013-02-21 | Otago Innovation Limited | Biomarkers |
| JP2011516038A (ja) | 2008-03-12 | 2011-05-26 | オタゴ イノベーション リミテッド | バイオマーカー |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| SG190572A1 (en) * | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009246263B2 (en) * | 2008-05-14 | 2014-08-21 | Amgen Inc. | Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer |
| US8455623B2 (en) | 2008-05-21 | 2013-06-04 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| CA2726087A1 (en) * | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| TW201006485A (en) * | 2008-06-03 | 2010-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2143441A1 (en) | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| CN102149825B (zh) * | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
| JP2012504606A (ja) * | 2008-10-01 | 2012-02-23 | ラディック インスティテュート フォー キャンサー リサーチ | 癌の治療方法 |
| CN102216331A (zh) * | 2008-10-17 | 2011-10-12 | 霍夫曼-拉罗奇有限公司 | 治疗方法 |
| TW201019961A (en) * | 2008-10-17 | 2010-06-01 | Genentech Inc | Combination therapy |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
| US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
| US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
| US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| EP2364368B1 (en) | 2008-11-07 | 2014-01-15 | Sequenta, Inc. | Methods of monitoring conditions by sequence analysis |
| PA8849001A1 (es) * | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| WO2010064089A1 (en) * | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| ES2726702T3 (es) | 2009-01-15 | 2019-10-08 | Adaptive Biotechnologies Corp | Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales |
| WO2010097386A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| EP2401296A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
| CA2753287A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| MA33208B1 (fr) | 2009-03-25 | 2012-04-02 | Genentech Inc | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci |
| MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| EP2417164A1 (en) | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-2/anti-c-met antibodies |
| WO2010122090A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Fgfr1c antibody combinations |
| WO2010129917A2 (en) | 2009-05-08 | 2010-11-11 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
| WO2010151416A1 (en) | 2009-06-25 | 2010-12-29 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| WO2011028811A2 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| KR101671378B1 (ko) * | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도 |
| KR101748707B1 (ko) * | 2009-11-27 | 2017-06-20 | 삼성전자주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트 |
| PT3904391T (pt) | 2010-03-10 | 2024-10-14 | Genmab As | Anticorpos monoclonais contra c-met |
| ES2993140T3 (en) | 2010-04-02 | 2024-12-23 | Amunix Pharmaceuticals Inc | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| JP2013529203A (ja) * | 2010-05-14 | 2013-07-18 | ジェネンテック， インコーポレイテッド | 治療方法 |
| EP2576622A4 (en) | 2010-06-01 | 2013-11-27 | Univ Monash | ON THE UNPROCESSED RECEPTOR TYROSINE KINASE C-MET TARGETED ANTIBODIES |
| PT3034608T (pt) * | 2010-06-22 | 2019-05-28 | Regeneron Pharma | Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana |
| EP2402370A1 (en) * | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| DK2596010T3 (en) | 2010-07-19 | 2017-07-31 | Otago Innovation Ltd | SIGNAL biomarkers |
| EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| MX2013002084A (es) | 2010-08-31 | 2013-05-09 | Genentech Inc | Biomarcadores y metodos de tratamiento. |
| KR20140019284A (ko) * | 2010-09-03 | 2014-02-14 | 아카데미아 시니카 | 항-C-Met 항체 및 이의 이용 방법들 |
| US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| RU2608644C2 (ru) | 2010-11-03 | 2017-01-23 | арДЖЕН-ИКС Н.В. | Антитела против белка рецептора с-мет |
| AU2011333738A1 (en) | 2010-11-24 | 2013-07-11 | Glaxo Group Limited | Multispecific antigen binding proteins targeting HGF |
| EP2646468B1 (en) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723771B1 (en) * | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| AR086823A1 (es) | 2011-06-30 | 2014-01-22 | Genentech Inc | Formulaciones de anticuerpo anti-c-met, metodos |
| TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| EP2748202B1 (en) | 2011-08-23 | 2018-07-04 | Roche Glycart AG | Bispecific antigen binding molecules |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
| SG11201400724SA (en) | 2011-09-19 | 2014-04-28 | Genentech Inc | Combination treatments comprising c-met antagonists and b-raf antagonists |
| CA2843771A1 (en) | 2011-09-20 | 2013-03-28 | Eli Lilly And Company | Anti-c-met antibodies |
| JP6219287B2 (ja) * | 2011-09-30 | 2017-10-25 | アブリンクス エン．ヴェー． | ｃ−Ｍｅｔに関連する生物学的物質 |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| KR101865223B1 (ko) | 2011-10-05 | 2018-06-08 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도 |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| AU2012322721B2 (en) | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
| EP2768982A4 (en) | 2011-10-21 | 2015-06-03 | Adaptive Biotechnologies Corp | QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS |
| US9926364B2 (en) | 2011-11-03 | 2018-03-27 | Argen-X N.V. | Chimeric human-llama antigens and methods of use |
| SG11201402485UA (en) | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
| EP2785741A1 (en) | 2011-12-02 | 2014-10-08 | Cancer Research Technology Limited | Antibodies against hgf - receptor and uses |
| US9824179B2 (en) | 2011-12-09 | 2017-11-21 | Adaptive Biotechnologies Corp. | Diagnosis of lymphoid malignancies and minimal residual disease detection |
| US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
| US8900582B2 (en) | 2011-12-22 | 2014-12-02 | Samsung Electronics Co., Ltd. | Deimmunized anti c-Met humanized antibodies and uses thereof |
| TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| EP3372694A1 (en) | 2012-03-05 | 2018-09-12 | Adaptive Biotechnologies Corporation | Determining paired immune receptor chains from frequency matched subunits |
| US10114028B2 (en) | 2012-03-20 | 2018-10-30 | Upstream Medical Technologies Limited | Biomarkers for pneumonia and acute decompensated heart failure |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| HUE029357T2 (en) | 2012-05-08 | 2017-02-28 | Adaptive Biotechnologies Corp | Preparations and devices for measuring and calibrating amplification distortion in multiplex PCR reactions |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| JP6628966B2 (ja) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたＦｃ領域を含む抗原結合分子 |
| CN105050618B (zh) * | 2012-06-21 | 2018-11-16 | 索伦托治疗有限公司 | 与c-Met结合的抗原结合蛋白 |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| EP3330384B1 (en) | 2012-10-01 | 2019-09-25 | Adaptive Biotechnologies Corporation | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| WO2015160439A2 (en) | 2014-04-17 | 2015-10-22 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
| TW202037609A (zh) | 2012-11-01 | 2020-10-16 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2914629A1 (en) | 2012-11-05 | 2015-09-09 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| MX361088B (es) | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
| US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
| KR101911048B1 (ko) | 2013-01-29 | 2018-10-24 | 삼성전자주식회사 | ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물 |
| HK1215959A1 (en) * | 2013-02-15 | 2016-09-30 | Perseus Proteomics Inc. | Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same |
| JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
| HK1220465A1 (zh) | 2013-03-06 | 2017-05-05 | Merrimack Pharmaceuticals, Inc. | 抗c-met串联fc双特异性抗体 |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
| US9535055B2 (en) | 2013-03-28 | 2017-01-03 | Samsung Electronics Co., Ltd. | Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker |
| US10214593B2 (en) | 2013-04-02 | 2019-02-26 | Samsung Electronics Co., Ltd. | Anti-idiotype antibody against anti-c-MET antibody |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2015134787A2 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| EP3187874B1 (en) * | 2014-08-25 | 2020-09-30 | Konica Minolta, Inc. | Detection method and detection device |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| ES2748295T3 (es) | 2014-09-16 | 2020-03-16 | Symphogen As | Anticuerpos anti-MET y composiciones |
| HUE049175T2 (hu) | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| CA2966201A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
| AU2015353581A1 (en) | 2014-11-25 | 2017-06-15 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
| JP6864953B2 (ja) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| EP4691556A3 (en) | 2014-12-19 | 2026-04-29 | H. Lundbeck A/S | Humanized anti-acth antibodies and use thereof |
| MA41375A (fr) | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| CA2976580A1 (en) | 2015-02-24 | 2016-09-01 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| CN113150147A (zh) * | 2015-03-16 | 2021-07-23 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
| EP3277294B1 (en) | 2015-04-01 | 2024-05-15 | Adaptive Biotechnologies Corp. | Method of identifying human compatible t cell receptors specific for an antigenic target |
| CN106188293A (zh) * | 2015-04-17 | 2016-12-07 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| WO2016165580A1 (zh) * | 2015-04-17 | 2016-10-20 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2017000059A1 (en) * | 2015-06-29 | 2017-01-05 | The University Of British Columbia | B1sp fusion protein therapeutics, methods, and uses |
| ITUB201586501U1 (it) * | 2015-10-26 | 2017-04-26 | Ballarini Paolo & Figli Spa | Recipiente per la cottura di alimenti |
| HRP20220064T1 (hr) * | 2015-10-30 | 2022-04-15 | F. Hoffmann - La Roche Ag | Zglobno modificirani fragmenti protutijela i postupci za pripravu |
| CN108350078A (zh) * | 2015-11-03 | 2018-07-31 | 默克专利股份公司 | 用于提高肿瘤选择性和抑制的双特异性抗体及其用途 |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CN105884897A (zh) * | 2016-04-23 | 2016-08-24 | 同济大学苏州研究院 | 抗c-Met单价抗体慢病毒快速表达及应用 |
| GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
| JP7274413B2 (ja) | 2016-09-23 | 2023-05-16 | マレンゴ・セラピューティクス，インコーポレーテッド | ラムダ及びカッパ軽鎖を含む多重特異性抗体分子 |
| EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| CN110709422B (zh) | 2017-04-19 | 2023-12-26 | 马伦戈治疗公司 | 多特异性分子及其用途 |
| JP7325339B2 (ja) * | 2017-05-30 | 2023-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | 新規な抗ｃ－Ｍｅｔ抗体およびその用途 |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
| EP3720881A1 (en) | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| CN113164777B (zh) | 2018-09-27 | 2024-12-13 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
| KR102433184B1 (ko) * | 2018-12-07 | 2022-08-17 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| KR102396194B1 (ko) | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP7737306B2 (ja) | 2019-02-21 | 2025-09-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CA3128519A1 (en) | 2019-02-21 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN115843312A (zh) | 2020-04-24 | 2023-03-24 | 马伦戈治疗公司 | 结合至t细胞相关癌细胞的多功能性分子及其用途 |
| CN112521507B (zh) * | 2020-08-10 | 2021-06-08 | 北京鼎成肽源生物技术有限公司 | 抗人c-Met人鼠嵌合单克隆抗体及其应用 |
| GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB2616354A (en) | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| BR112023020801A2 (pt) | 2021-04-08 | 2023-12-12 | Byondis Bv | Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica |
| WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| IL318499A (en) | 2022-07-30 | 2025-03-01 | Pinetree Therapeutics Inc | Compounds for targeted lysosomal degradation and methods of using them |
| US12060148B2 (en) | 2022-08-16 | 2024-08-13 | Honeywell International Inc. | Ground resonance detection and warning system and method |
| JP2025529196A (ja) | 2022-09-01 | 2025-09-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 間葉系上皮転換因子（ｍｅｔ）標的薬を使用して非小細胞肺がんを治療する方法 |
| US20240228620A1 (en) | 2022-10-06 | 2024-07-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| EP4713360A1 (en) | 2023-05-19 | 2026-03-25 | Les Laboratoires Servier | Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025025434A1 (zh) * | 2023-08-02 | 2025-02-06 | 百泰生物药业有限公司 | EGFR/c-Met双特异性抗体及其应用 |
| WO2025144958A1 (en) * | 2023-12-29 | 2025-07-03 | AffyImmune Therapeutics Inc. | Novel c-met binding agents and methods of treatment |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| WO2026037841A1 (en) | 2024-08-12 | 2026-02-19 | ONA Therapeutics S.L. | Anti-fgfr4 molecules and uses thereof |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) * | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8318575D0 (en) | 1983-07-08 | 1983-08-10 | Cobbold S P | Antibody preparations |
| US5169939A (en) * | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) * | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5871959A (en) * | 1989-12-27 | 1999-02-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing hepatocycte growth factor/scatter factor and related cell lines |
| US5362716A (en) * | 1989-12-27 | 1994-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines |
| US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
| EP0571387B1 (en) | 1990-09-14 | 2003-12-17 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | A non-mitogenic competitive hgf antagonist |
| US5968509A (en) * | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
| US5264365A (en) * | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5508192A (en) * | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| CA2102595C (en) | 1991-05-10 | 2003-01-14 | Paolo Comoglio | Truncated forms of the hepatocyte growth factor (hgf) receptor |
| US5227158A (en) * | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| CA2118508A1 (en) * | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| WO1993023550A2 (en) | 1992-05-18 | 1993-11-25 | Genentech, Inc. | Activation of oligomerizing receptors by using fused receptor ligands |
| US5316921A (en) * | 1992-05-18 | 1994-05-31 | Genentech, Inc. | Single-chain hepatocyte growth factor variants |
| US5328837A (en) * | 1992-05-18 | 1994-07-12 | Genentech, Inc. | Hepatocyte growth factor protease domain variants |
| ATE222603T1 (de) * | 1992-05-18 | 2002-09-15 | Genentech Inc | Hepatozytwachstumfaktor variante |
| ATE160585T1 (de) | 1992-09-18 | 1997-12-15 | Us Gov Health & Human Serv | Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| WO1995001376A1 (en) | 1993-06-30 | 1995-01-12 | Pharmacia S.P.A. | Peptide inhibitors of mitogenesis and motogenesis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) * | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6121022A (en) * | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5646036A (en) * | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| AU2660397A (en) * | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| US6083715A (en) * | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| DE19858253A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Pharma Gmbh | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden |
| EP1240337B1 (en) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| CA2450793A1 (en) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| NZ542784A (en) * | 2002-08-19 | 2008-07-31 | Astrazeneca Ab | Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| BRPI0407446A (pt) | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| PT1718677E (pt) * | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| CA2575402A1 (en) * | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
-
2005
- 2005-08-04 CA CA002575402A patent/CA2575402A1/en not_active Abandoned
- 2005-08-04 ES ES05804027T patent/ES2344793T3/es not_active Expired - Lifetime
- 2005-08-04 CN CN2005800337921A patent/CN101035808B/zh not_active Expired - Fee Related
- 2005-08-04 PL PL05804027T patent/PL1773885T3/pl unknown
- 2005-08-04 MX MX2007001470A patent/MX2007001470A/es active IP Right Grant
- 2005-08-04 CN CN201510175249.0A patent/CN104804095A/zh active Pending
- 2005-08-04 CN CN201210336983.7A patent/CN102942631B/zh not_active Expired - Fee Related
- 2005-08-04 JP JP2007524960A patent/JP5068651B2/ja not_active Expired - Fee Related
- 2005-08-04 NZ NZ552485A patent/NZ552485A/en not_active IP Right Cessation
- 2005-08-04 EP EP05804027A patent/EP1773885B1/en not_active Expired - Lifetime
- 2005-08-04 SI SI200531055T patent/SI1773885T1/sl unknown
- 2005-08-04 HR HR20100385T patent/HRP20100385T1/hr unknown
- 2005-08-04 BR BRPI0513666-0A patent/BRPI0513666A/pt not_active IP Right Cessation
- 2005-08-04 ZA ZA200701656A patent/ZA200701656B/xx unknown
- 2005-08-04 RU RU2007107909/10A patent/RU2398777C2/ru active
- 2005-08-04 ME MEP-2010-306A patent/ME01803B/me unknown
- 2005-08-04 AU AU2005267720A patent/AU2005267720B2/en not_active Expired
- 2005-08-04 DE DE602005020799T patent/DE602005020799D1/de not_active Expired - Lifetime
- 2005-08-04 DK DK05804027.0T patent/DK1773885T3/da active
- 2005-08-04 PT PT05804027T patent/PT1773885E/pt unknown
- 2005-08-04 WO PCT/US2005/027626 patent/WO2006015371A2/en not_active Ceased
- 2005-08-04 KR KR1020077005123A patent/KR101397851B1/ko not_active Expired - Fee Related
- 2005-08-04 RS RSP-2010/0306A patent/RS51326B/sr unknown
- 2005-08-04 AT AT05804027T patent/ATE465181T1/de active
- 2005-08-04 US US11/196,917 patent/US7476724B2/en active Active
-
2006
- 2006-10-02 US US11/537,760 patent/US7892550B2/en not_active Expired - Fee Related
-
2007
- 2007-01-08 IL IL180588A patent/IL180588A/en active IP Right Grant
- 2007-03-02 NO NO20071188A patent/NO20071188L/no not_active Application Discontinuation
-
2010
- 2010-07-06 CY CY20101100621T patent/CY1111622T1/el unknown
-
2011
- 2011-01-18 US US13/008,836 patent/US20110300146A1/en not_active Abandoned
- 2011-07-28 US US13/193,532 patent/US20120082662A1/en not_active Abandoned
- 2011-07-28 IL IL214325A patent/IL214325A/en active IP Right Grant
- 2011-07-28 US US13/193,537 patent/US20120082663A1/en not_active Abandoned
- 2011-10-05 JP JP2011221431A patent/JP2012040012A/ja active Pending
-
2014
- 2014-03-14 US US14/212,854 patent/US20140227258A1/en not_active Abandoned
-
2016
- 2016-05-03 IL IL245462A patent/IL245462A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01803B (me) | Humanizovani anti-cmet antagonisti | |
| US7723484B2 (en) | Anti-EGFR antibodies | |
| US9580498B2 (en) | Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial growth factor to its receptor, and coding sequence | |
| CN115057933B (zh) | 抗met抗体及其应用 | |
| HRP20250474T1 (hr) | Antitijela koja se vežu za egfr i cmet | |
| JP2014509835A5 (me) | ||
| RU2019109452A (ru) | АНТИ-FcRH5 АНТИТЕЛА | |
| JP2014158469A5 (me) | ||
| HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu | |
| JP2013056885A5 (me) | ||
| JP2017514461A5 (me) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| CN101434654A (zh) | 可中和的hgf表位和与其结合的中和抗体 | |
| KR101739489B1 (ko) | 인간 유래 항-인간 표피 생장인자 수용체 항체 및 그의 코딩 유전자와 용도 | |
| HRP20131107T1 (hr) | Anti-notch1 nrr-protutijela i postupak njihove uporabe | |
| JP2009525764A5 (me) | ||
| CN101415811A (zh) | 针对肝细胞生长因子的人源化单克隆抗体 | |
| CN101346394A (zh) | TGF-β结合组合物 | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2023546743A5 (me) | ||
| KR20110011710A (ko) | 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체 | |
| JP2014526891A5 (me) | ||
| CN116514970B (zh) | 靶向rankl的治疗性抗体 | |
| US20150110788A1 (en) | Bispecific antibodies with an fgf2 binding domain | |
| KR101943724B1 (ko) | Ang2 항체 |